Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis

Abstract

To perform a systemic review and meta-analysis of the diagnostic accuracy of PET (CT) and metaiodobenzylguanidine (MIBG) for diagnosing neuroblastoma (NB), electronic databases were searched as well as relevant references and conference proceedings. The diagnostic accuracy of MIBG and PET (CT) was calculated for NB, primary NB, and relapse/metastasis of NB based on their sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUSROC) in terms of per-lesion and per-patient data. A total of 40 eligible studies comprising 1134 patients with 939 NB lesions were considered for the meta-analysis. For the staging of NB, the per-lesion AUSROC value of MIBG was lower than that of PET (CT) [0.8064±0.0414 vs. 0.9366±0.0166 (P<0.05)]. The per-patient AUSROC value of MIBG and PET (CT) for the diagnosis of NB was 0.8771±0.0230 and 0.6851±0.2111, respectively. The summary sensitivity for MIBG and PET (CT) was 0.79 and 0.89, respectively. The summary specificity for MIBG and PET (CT) was 0.84 and 0.71, respectively. PET (CT) showed higher per-lesion accuracy than MIBG and might be the preferred modality for the staging of NB. On the other hand, MIBG has a comparable diagnosing performance with PET (CT) in per-patient analysis but shows a better specificity.

Keywords

positron emission tomography-computed tomography / metaiodobenzylguanidine / neuroblastoma / diagnostic accuracy / meta-analysis

References

[1] PintoNR, ApplebaumMA, VolchenboumSL, et al. . Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol, 2015, 33(27): 3008-3017 PMID: 26304901 PMCID: 4567703

[2] MatthayKK, ShulkinB, LadensteinR, et al. . Criteria for evaluation of disease extent by ¹²³I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer, 2010, 102(9): 1319-1326 PMID: 20424613 PMCID: 2865749

[3] CohnSL, PearsonAD, LondonWB, et al. . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 2009, 27(2): 289-297 PMID: 19047291 PMCID: 2650388

[4] PaltielHJ, GelfandMJ, ElgazzarAH, et al. . Neural crest tumors: I-123 MIBG imaging in children. Radiology, 1994, 190(1): 117-121 PMID: 8259387

[5] OlivierP, ColarinhaP, FettichJ, et al. . Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging, 2003, 30(5): B45-B50 PMID: 12658506

[6] BonninF, LumbrosoJ, TenenbaumF, et al. . Refining interpretation of MIBG scans in children. J Nucl Med, 1994, 35(5): 803-810 PMID: 8176462

[7] UsluL, DonigJ, LinkM, et al. . Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med, 2015, 56(2): 274-286 PMID: 25572088

[8] DecarolisB, SchneiderC, HeroB, et al. . Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol, 2015, 31(7): 944-951

[9] CzapiewskiP, KuncM, HaybaeckJ. Genetic and molecular alterations in olfactory neuroblastoma-implications for pathogenesis, prognosis and treatment. Oncotarget, 2016, 7(32): 52584-52596 PMID: 27256979 PMCID: 5239575

[10] BrisseH M, CarvilleMB, GranataC, et al. . International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology, 2011, 261(1): 243-257 PMID: 21586679

[11] WhitingPF, RutjesAW, WestwoodME, et al. . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536 PMID: 22007046

[12] LauJ, IoannidisJP, SchmidCH. Quantitative synthesis in systematic reviews. Ann Intern Med, 1997, 127: 820-826 PMID: 9382404

[13] HigginsJP, ThompsonSG, DeeksJJ, et al. . Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-60 PMID: 12958120 PMCID: 192859

[14] ReitsmaJB, GlasAS, RutjesAW, et al. . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol, 2005, 58(10): 982-990 PMID: 16168343

[15] ZwindermanAH, BossuytPM. We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med, 2008, 27(5): 687-697 PMID: 17611957

[16] DhullVS, SharmaP, PatelC, et al. . Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with ¹³¹I-MIBG scintigraphy. Nucl Med Commun, 2015, 36(10): 1007-1013 PMID: 26049371

[17] GilTY, Lee doK, LeeJM, et al. . Clinical experience with 18F-fluorodeoxyglucose positron emission tomography and ¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients. Korean J Pediatr, 2014, 57(6): 278-286 PMID: 25076973 PMCID: 4115069

[18] PiccardoA, PuntoniM, LopciE, et al. . Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol, 2014, 41(6): 1046-1056

[19] LuMY, LiuYL, ChangHH, et al. . Characterization of neuroblastic tumors using 18F-FDOPA PET. Soc Nucl Med, 2013, 54(1): 42-49

[20] LopciE, PiccardoA, NanniC, et al. . 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/M. Clin Nucl Med, 2012, 37(4): e73-e78 PMID: 22391727

[21] PiccardoA, LopciE, ConteM, et al. . Comparison of 18F-dopa PET/CT and ¹²³I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol, 2012, 39(1): 57-71

[22] MelzerHI, CoppenrathE, SchmidI, et al. . ¹²³I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol, 2011, 38(9): 1648-1658

[23] PapathanasiouND, GazeMN, SullivanK, et al. . 18F-FDG PET/CT and ¹²³I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med, 2011, 52(4): 519-525 PMID: 21421719

[24] RozovskyK, KoplewitzBZ, KrauszY, et al. . Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AM J Roentgenol, 2008, 190(4): 1085-1090

[25] El-MaghrabyT. ¹³¹I-MIBG in the diagnosis of primary and metastatic neuroblastoma. Gulf J Oncol, 2007, 2: 33-41

[26] HammamiH, HassineL, MhiriA, et al. . Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases. Tunis Med, 2007, 85(5): 413-416 PMID: 17657930

[27] FranziusC, HermannK, WeckesserM, et al. . Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with ¹²³I-MIBG SPECT/CT. J Nucl Med, 2006, 47(10): 1635-1642 PMID: 17015899

[28] Shah SyedGM, NaseerH, UsmaniGN, et al. . Role of iodine-131 MIBG scanning in the management of paediatric patients with neuroblastoma. Med Princ Pract, 2004, 13(4): 196-200 PMID: 15181323

[29] HashimotoT, KoizumiK, NishinaT, et al. . Clinical usefulness of iodine-123-MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Ann Nucl Med, 2003, 17(8): 633-640 PMID: 14971604

[30] PflugerT, SchmiedC, PornU, et al. . Integrated imaging using MRI and ¹²³I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Am J Roentgenol, 2003, 181(4): 1115-1124

[31] Hervas BenitoI, Rivas SanchezA, Bello ArquesP. Value of ¹²³I-MIBG scanning, neuron-specific enolase and serum ferritin in the diagnosis and follow-up of patients with neuroblastoma. Rev Esp Med Nucl, 2001, 20(5): 369-376 PMID: 11470071

[32] BiasottiS, GaraventaA, VillavecchiaGP, et al. . False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol, 2000, 35(2): 153-155 PMID: 10918246

[33] SchillingFH, BihlH, JacobssonH, et al. . Combined 111In-pentetreotide scintigraphy and ¹²³I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol, 2000, 35(6): 688-691 PMID: 11107147

[34] OkuyamaC, UshijimaY, SugiharaH, et al. . ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma. Kaku Igaku JPN J Nucl Med, 1998, 35(9): 835-842

[35] Is the expression of somatostatin receptors a prognostic factor? Anticancer Res, 1997, 17(3B

[36] Shalaby-RanaE, MajdM, AndrichMP, et al. . In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome. Clin Nucl Med, 1997, 225): 315-319 PMID: 9152532

[37] Hadj-DjilaniNL, LebtahiNE, DelaloyeAB, et al. . Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med, 1995, 22(4): 322-329 PMID: 7607262

[38] Labreveux de CervensC, HartmannO, BonninF, et al. . What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age. Med Pediatr Oncol, 1994, 22(2): 107-114 PMID: 8259095

[39] GordonI, PetersAM, GutmanA, et al. . Skeletal assessment in neuroblastoma—the pitfalls of iodine-123-MIBG scans. J Nucl Med, 1990, 31(2): 129-134 PMID: 2313350

[40] HeymanS, EvansAE, D'AngioGJ. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol, 1988, 16(5): 337-340 PMID: 3185361

[41] EdelingCJ, FrederiksenPB, KamperJ, et al. . Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine. Clin Nucl Med, 1987, 12(8): 632-637 PMID: 3665302

[42] ShapiroB. MIBG in the diagnosis and therapy of neuroblastoma and pheochromocytoma. Nucl Med, 1987, 1: 11-20

[43] HoefnagelCA, VoûtePA, de KrakerJ, et al. . Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med, 1987, 28(3): 308-314 PMID: 3102701

[44] CaballeroO, FerrisJ, VerdeguerA, et al. . Iodine-131 metaiodobenzylguanidine. Soc Nucl Med, 1986, 27(6): 868-869

[45] HadleyGP, RabeE. Scanning with iodine-131 MIBG in children with solid tumors: an initial appraisal. Soc Nucl Med, 1986, 27(5): 620-626

[46] HeymanS, EvansAE. Iodine-131-metaiodobenzylguanidine (I-131-MIBG) in the diagnosis of neuroblastoma. J Nuc Med, 1986, 27: 931

[47] FeineU, Muller-SchauenburgW, TreunerJ, et al. . Metaiodobenzylguanidine (MIBG) labeled with ml/nil in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology Held in Rome. Med Pediatr Oncol, 1987, 15(4): 181-187 PMID: 3309603

[48] KimmingB, BrandeisWE, EisenhutM, et al. . Szintigraphische Diagnostik des Neuroblastoms mit meta-Jod-Benzylguanidin. Klin Padiat, 1986, 198(3): 224-229

[49] MunknerT. Scintigraphy of neuroblastoma. Nuklearmedizin, 1986436-438

[50] Odano MasayukiT, SakaK. Significance of I-131 meta-iodobenzylguanidine scintigraphy in diagnosing neuroblastoma. Kakii Igakit, 1986, 22(11): 1685-1688

[51] FischerM, GalanskiM, WinterbergB, et al. . Localization procedures in pheochromocytoma and neuroblastoma. Cardiology, 1985, 72(1): 143-146 PMID: 3902227

[52] GeattiO, ShapiroB, SissonJC, et al. . Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. Soc Nucl Med, 1985, 26(7): 736-742

[53] LumbrosoJ, HartmannO, LeerleJ, et al. . Scintigraphic detection of neuroblastoma using 111I and 121I labelled metaiodobenzyl-guanidine. Eur J Nucl Med, 1985, 11: A16

[54] Muller-GartnerHW, ErttmannR, HelmkeK. Die Szintigraphie mil Radiojod-[Meta-Jod-Benzylguanidin] in der Diagnostik des Neuroblastoms. Nuklearmedizin, 1985, 24(5): 222-226 PMID: 3912731

[55] FeineU, TreunerJ, NiethammerD, et al. . Erste untenshungen zur scintigraphischen darstellung von neuroblastomen mit 131-J-meta-benzylguanidin. Nuc Compaci, 1984, 15: 23-26

[56] BleekerG, TytgatGA, AdamJA, et al. . ¹²³I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev, 2015, 29(9): CD009263

[57] VikTA, PflugerT, KadotaR, et al. . ¹²³I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer, 2009, 52(7): 784-790 PMID: 19185008

[58] BoubakerA B, DelaloyeA. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med, 2003, 47(1): 31-40 PMID: 12714952

[59] PiccardoA, LopciE, ConteM, et al. . PET/CT imaging in neuroblastoma. Q J Nucl Med Mol Imaging, 2013, 57(1): 29-39 PMID: 23474633

[60] NaranjoA, ParisiMT, ShulkinBL, et al. . Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer, 2011, 56(7): 1041-1045 PMID: 21328522 PMCID: 4581540

[61] PepeG, BombardieriE, LorenzoniA, et al. . Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors. PET Clin, 2014, 9(1): 11-26 PMID: 25029930

[62] TaggartDR, HanMM, QuachA, et al. . Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and 18F-fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol, 2009, 27(32): 5343-5349 PMID: 19805691 PMCID: 2773221

[63] KushnerBH, YeungHW, LarsonSM, et al. . Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol, 2001, 19(14): 3397-3405 PMID: 11454888

[64] KroissA, ShulkinBL, UprimnyC, et al. . 68Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ¹²³I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging, 2015, 42(1): 33-41 PMID: 25134670

[65] KroissA, PutzerD, UprimnyC, et al. . Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and ¹²³I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging, 2011, 38(5): 865-873 PMID: 21279352

[66] CistaroA, QuartuccioN, CaobelliF, et al. . ¹²⁴I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur, 2015, 18(2): 102-106 PMID: 26315872